Condition: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Sponsor: Princess Maxima Center for Pediatric Oncology
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol D is a phase I/II trial evaluating the safety and efficacy of trametinib in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the RAS-RAF-MAPK pathway.
This description comes directly from the study's public registry record.
Anne Elsinghorst · +316 5000 6270 · hem-ismart@prinsesmaximacentrum.nl
Always discuss trial participation with your own doctor first.
| St. Anna Kinderspital | Vienna, Austria | Not Yet Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Not Yet Recruiting |
| Rigshospitalet Copenhagen | Copenhagen, Denmark | Recruiting |
| Helsinki University Hospital, New Children's Hospital | Helsinki, Finland | Not Yet Recruiting |
| Hôpital des Enfants GH Pellegrin - CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| CHRU Lille - Hôpital Jeanne de Flandre | Lille, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Not Yet Recruiting |
| Hopital La Timone - Enfants | Marseille, France | Not Yet Recruiting |
| CHU Nantes Hôpital Mère-Enfant | Nantes, France | Not Yet Recruiting |
| Hôpital Robert Debré | Paris, France | Not Yet Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Not Yet Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05658640